Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP-333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Linaclotide (Primary)
- Indications Colorectal cancer; Constipation; Irritable bowel syndrome; Visceral pain
- Focus Pharmacokinetics
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 30 Apr 2021 Planned End Date changed from 15 Apr 2021 to 15 Apr 2022.
- 29 Apr 2020 Planned End Date changed from 15 Apr 2020 to 15 Apr 2021.